Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

15.36 3.43

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.8

Max

15.7

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+98.92% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	130M 1.3B
Ouverture précédente	11.93
Clôture précédente	15.36

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 août 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19 août 2026, 23:56 UTC

Peloton Interactive Inc shares are lower in after-market hours with no specific news to explain the decline. The stock remains below its 20-day moving average.

19 août 2026, 23:56 UTC

Shares of Nova Ltd. rose in after-market trading, despite earlier fluctuations and remaining below its 20-day moving average.

19 août 2026, 23:56 UTC

Certara Inc. shares are lower in after-hours trading, showing slight declines since Wednesday's close while remaining above the 20-day moving average.

19 août 2026, 23:56 UTC

CareDx Inc shares are higher in after-market hours, remaining above their 20-day moving average. No specific news was identified to explain the movement.

19 août 2026, 23:56 UTC

Correlated Moves

Pinnacle West Capital shares are modestly higher in after-market trading, tracking a similar rise in PG&E Corp, indicating potential market correlation.

19 août 2026, 23:56 UTC

Pentair PLC shares are lower in after-market trading, reflecting routine activity and slight declines since Wednesday's close. The price remains near the one-month midpoint.

19 août 2026, 23:56 UTC

Best Buy Co Inc shares are higher in after-market trading, fluctuating slightly while remaining above their 20-day moving average. No specific news was identified.

19 août 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

19 août 2026, 23:56 UTC

Quest Diagnostics Inc shares are higher in after-market hours, continuing a trend of four consecutive sessions finishing above their 20-day moving average.

19 août 2026, 23:56 UTC

GSI Technology Inc's shares are higher in after-market trading, despite a recent decline and ongoing weakness below the 20-day moving average.

19 août 2026, 23:56 UTC

Invesco DB Agriculture Fund is higher in after-market trading, reflecting a notable upward move since Wednesday's close and trading near its one-month range.

19 août 2026, 23:56 UTC

CF Industries remains roughly flat in after-market hours, trading near the middle of its one-month range and slightly below its 20-day moving average.

19 août 2026, 23:56 UTC

Apollo Global Management shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

19 août 2026, 23:56 UTC

Ares Capital Corp shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock remains above its 20-day moving average.

19 août 2026, 23:56 UTC

Huntington Bancshares Inc shares are higher in after-market trading, despite no specific news. The stock remains below its 20-day moving average.

19 août 2026, 23:56 UTC

FactSet Research Systems is trading lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

19 août 2026, 23:56 UTC

Shoals Technologies Group Inc is trading lower in after-market hours, continuing a downward trend without any specific news to explain the movement.

19 août 2026, 23:56 UTC

News

Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19 août 2026, 23:52 UTC

News

Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19 août 2026, 23:52 UTC

Progressive Corp shares are higher in after-market hours, reflecting a modest gain since Wednesday's close. The stock remains above its 20-day moving average.

19 août 2026, 23:51 UTC

Doximity Inc shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19 août 2026, 23:51 UTC

Peabody Energy shares are lower in after-market trading, reversing an earlier gain. The stock remains above its 20-day moving average.

19 août 2026, 23:51 UTC

Patria Investments Ltd is trading higher in after-market hours, reaching 2.45% above Wednesday's close and showing strong momentum above its 20-day moving average.

19 août 2026, 23:51 UTC

Workday Inc. shares are higher in after-market trading, continuing a month-long upward trend and remaining above the 20-day moving average.

19 août 2026, 23:51 UTC

Pinterest Inc. shares moved lower in after-market trading, retracing earlier gains and remaining below their 20-day moving average.

19 août 2026, 23:51 UTC

Kilroy Realty Corp shares are lower in after-market trading, continuing a decline since Wednesday's close and positioned below its 20-day moving average.

19 août 2026, 23:51 UTC

Take-Two Interactive shares are higher in after-market hours, recovering from earlier lows. No specific news was identified to explain the price movement.

19 août 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19 août 2026, 23:51 UTC

Mixed trading in European equities as Eurozone inflation rises to 2.9% and German Bund yields hit a 12-year high amid geopolitical tensions.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

98.92% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 98.92%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.